LUMINARY THERAPEUTICS PROVIDING INCREASED ACCESS TO TREAT UNDERSERVED PATIENT POPULATIONS A clinical-stage company developing innovative allogeneic cell therapies with a unique Gamma 2.0+ platform to target solid tumors and autoimmune disorders Luminary Therapeutics, Minneapolis, MN
LUMINARY THERAPEUTICS

Luminary is overcoming key challenges facing the CAR T industry

CAR-T cell therapy is revolutionary in cancer treatment. While producing many remarkable clinical results, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Challenges to effective CAR-T cell therapy include antigen escape, limited tumor infiltration and others.

CAR-T cell therapy also has manufacturing challenges that include high cost of production and long lead times contributing to delays in administering the therapies.

Luminary has developed a platform coupled with a novel set of CARs that address these challenges head on for both hematological malignancy and solid tumors.

OUR PLATFORM

Industry-leading platform driving persistence and durability at a lower cost

Allogeneic Aurora Platform

At Luminary, we are keenly focused on addressing the many challenges facing CAR T therapies. We developed a unique allogeneic platform unlike any other. We are utilizing that platform to develop cellular therapies that bring new advances to the table. Our work is helping to deliver new standards of care for B-Cell malignancies and specific B-Cell mediated autoimmune diseases. At the same time, we are delivering ground-breaking science for solid tumors. And we are doing this at lower therapy costs.

Less relapse, more recovery, less financial strain. This is our mission.

Explore our Platform

THREE COMPLEMENTARY PROGRAMS

Advancing CAR-T therapy with innovative approaches

Building on our allogeneic Gamma 2.0+ platform, Luminary is advancing complementary therapeutic approaches to address common challenges in CAR-T therapy, including antigen escape, treatment durability and effectiveness across difficult-to-treat diseases.

Diagram illustrating Luminary's Dual-Targeting Split CAR technology

Dual-Targeting Split CAR

Maximizing T-Cell Fitness for Multi-Antigen Targeting

Our Split Co-Stim Dual CAR program targets multiple cancer antigens with a single engineered T cell therapy. The approach aims to improve cancer cell elimination, sustain T cell activity, and overcome the suppressive environment surrounding solid tumors.

Learn More
Diagram showing BAFF-Ligand CAR targeting multiple B-cell receptors

BAFF-Ligand CAR

Overcoming Antigen Escape for Durable Remission

Our BAFF Ligand-Based CAR program addresses antigen escape, a major cause of relapse following CAR T-cell therapy. By targeting multiple receptors on cancerous B cells, this approach aims to promote more durable treatment responses.

Learn More
Diagram illustrating BEACON T-cell interactions with tumor and immune cells

BEACON Therapy

Transforming Gamma Delta T Cells into Powerful Anticancer Sentinels

Our BEACON program combats advanced solid tumors by combining CAR-T cell targeting with antigen-presenting capabilities in a single engineered cell therapy. This approach aims to directly eliminate cancer cells while activating the body's broader immune response.

Learn More

Copyright © 2019–2026 All Rights Reserved by Luminary Therapeutics.